T
Topas Therapeutics
Harnessing the liver’s natural immunology capabilities to address areas of major unmet medical need
About Topas Therapeutics
Topas Therapeutics is a biotechnology company focused on developing innovative therapies for autoimmune diseases by leveraging the liver's natural tolerance induction capabilities. The company primarily serves patients suffering from conditions such as pemphigus vulgaris, a rare autoimmune disease. Operating in the biopharmaceutical market, Topas Therapeutics employs a business model centered around research and development, clinical trials, and eventual commercialization of its proprietary treatments. Revenue is generated through a combination of funding rounds, partnerships with larger pharmaceutical companies, and future sales of approved therapies. The company recently raised USD 26 million in Series B financing to further its research and development efforts. Key clients include healthcare providers, research institutions, and patients.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 67.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Autoimmune, Chronic Disease, Sustainable Development Goals, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Topas Therapeutics is 1.6K monthly website visits, up 14.3% over the last three months. Topas Therapeutics's team grew 5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Topas Therapeutics in the Hamburg ecosystem
The Topas Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Epidarex Capital
EMBL Ventures
Gimv
Evotec
Boehringer Ingelheim Venture Fund
BioMedVC
Vesalius Biocapital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Topas Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Topas Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










